Sionna Therapeutics Inc 2026年季度报告

FORM 10-Q_________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-42504_________________________ SIONNA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)_________________________ (617) 819-2020Registrant’s telephone number, including area code Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for thepast 90 days. YesNoIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YesNoIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 ofthe Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesNoThe number of shares of registrant’s common stock outstanding as of April 30, 2026 was 45,150,330. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements about us and ourindustry that involve substantial risks and uncertainties, and which are made pursuant to the safe harbor provisions of Section 27Aof the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, asamended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report,including statements regarding our future results of operations and financial position, business strategy, product candidates,preclinical studies and clinical trials, results of preclinical studies and clinical trials, research and development costs, regulatoryapprovals, commercial strategy, timing and likelihood of success, as well as plans and objectives of management for futureoperations, are forward-looking statements. Although we believe that the expectations reflected in these forward-lookingstatements are reasonable, these statements involve known and unknown risks, uncertainties and other important factors that arein some cases beyond our control and may cause our actual results, performance or achievements to be materially different fromany future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,”“plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative ofthese terms or other similar expressions. Forward-looking statements contained in this Quarterly Report include, but are notlimited to, statements about: •the initiation, timing, progress and results of our research and development programs, preclinical studies and clinical trials;•the ability of clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results, and theability of our earlier clinical trials and preclinical studies to predict later clinical trial results;•the timing, scope and likelihood of regulatory filings and approvals of our product candidates;•the implementation of our business model, and strategic plans for our business, programs, and current and future productcandidates;•our ability to obtain additional cash and the sufficiency of our existing cash, cash equivalents and investments inmarketable securities to fund our future operating expenses and capital expenditure requirements;•the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additionalfinancing;•the size and growth potential of the markets for our product candidates, and our ability to serve those markets;•our potential and ability to successfully manufacture and supply our current and future product candidates for clinical trialsand for commercial use, if